[
    [
        {
            "time": "2021-10-26",
            "original_text": "A股共发生133宗大宗交易成交33.93亿元（10月26日）",
            "features": {
                "keywords": [
                    "大宗交易",
                    "A股",
                    "成交额"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股共发生133宗大宗交易成交33.93亿元（10月26日）",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药跌7.26% 西南证券高点发研报建议持有",
            "features": {
                "keywords": [
                    "泰格医药",
                    "股价下跌",
                    "西南证券",
                    "研报"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "泰格医药跌7.26% 西南证券高点发研报建议持有",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药现2笔大宗交易 共成交4,184.61万元",
            "features": {
                "keywords": [
                    "泰格医药",
                    "大宗交易",
                    "成交额"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药现2笔大宗交易 共成交4,184.61万元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "焦巍管理的银华富裕基金披露三季度最新持仓：配置医药、白酒行业 泰格医药(300347.SZ)位列第一重仓股",
            "features": {
                "keywords": [
                    "银华富裕基金",
                    "焦巍",
                    "泰格医药",
                    "重仓股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "焦巍管理的银华富裕基金披露三季度最新持仓：配置医药、白酒行业 泰格医药(300347.SZ)位列第一重仓股",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "财信证券给予泰格医药推荐评级，新冠疫情影响减弱，业绩增长超预期，目标价格为189.00-202.50元",
            "features": {
                "keywords": [
                    "泰格医药",
                    "财信证券",
                    "推荐评级",
                    "业绩增长",
                    "目标价格"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "财信证券给予泰格医药推荐评级，新冠疫情影响减弱，业绩增长超预期，目标价格为189.00-202.50元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "财信证券：给予泰格医药买入评级，目标价位202.5元",
            "features": {
                "keywords": [
                    "泰格医药",
                    "财信证券",
                    "买入评级",
                    "目标价位"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "财信证券：给予泰格医药买入评级，目标价位202.5元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "“金句专业户”焦巍又反思：坦言自身投资模式现阶段或落后，也要减少噪音干扰，增加长期绝对回报",
            "features": {
                "keywords": [
                    "焦巍",
                    "投资模式",
                    "反思",
                    "长期回报"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "\"金句专业户\"焦巍又反思：坦言自身投资模式现阶段或落后，也要减少噪音干扰，增加长期绝对回报",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "泰格医药(300347)：三季报业绩超预期 加速拓展全球化布局",
            "features": {
                "keywords": [
                    "泰格医药",
                    "三季报",
                    "业绩超预期",
                    "全球化布局"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(300347)：三季报业绩超预期 加速拓展全球化布局",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "泰格医药成立产业运营公司，经营范围含检验检测服务等",
            "features": {
                "keywords": [
                    "泰格医药",
                    "产业运营公司",
                    "检验检测服务"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药成立产业运营公司，经营范围含检验检测服务等",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "泰格医药：医药研发持续发力，三季度营收超13亿",
            "features": {
                "keywords": [
                    "泰格医药",
                    "医药研发",
                    "三季度营收"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药：医药研发持续发力，三季度营收超13亿",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "天风证券：维持泰格医药(300347.SZ)“买入”评级 Q3业绩提速 全年业绩有望持续高增",
            "features": {
                "keywords": [
                    "泰格医药",
                    "天风证券",
                    "买入评级",
                    "Q3业绩",
                    "全年业绩"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天风证券：维持泰格医药(300347.SZ)“买入”评级 Q3业绩提速 全年业绩有望持续高增",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "干货！2021年中国医药研发外包(CRO)行业龙头分析——康龙化成：被低估的CRO龙头",
            "features": {
                "keywords": [
                    "医药研发外包",
                    "CRO",
                    "康龙化成",
                    "龙头分析"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "干货！2021年中国医药研发外包(CRO)行业龙头分析——康龙化成：被低估的CRO龙头",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "天风证券维持泰格医药买入评级：Q3业绩提速，全年业绩有望持续高增",
            "features": {
                "keywords": [
                    "泰格医药",
                    "天风证券",
                    "买入评级",
                    "Q3业绩",
                    "全年业绩"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天风证券维持泰格医药买入评级：Q3业绩提速，全年业绩有望持续高增",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[权益变动]泰格医药(03347.HK)被NINETY ONE UK LIMITED减持2.27万股 减持股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "权益变动",
                    "减持",
                    "NINETY ONE UK LIMITED"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[权益变动]泰格医药(03347.HK)被NINETY ONE UK LIMITED减持2.27万股 减持股份",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "高瓴、张坤减持“眼茅”，葛兰却大手笔加仓",
            "features": {
                "keywords": [
                    "高瓴",
                    "张坤",
                    "减持",
                    "葛兰",
                    "加仓"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "高瓴、张坤减持“眼茅”，葛兰却大手笔加仓",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]